INDIANAPOLIS--(BUSINESS WIRE)--The biotechnology and pharmaceutical industries are at a crossroads. Both industries are turning to new partners and contract service providers out of a rising need to share risks, reduce costs and improve productivity in the pursuit of new drug therapies that often take more than $1 billion to bring to market. Indiana’s life sciences companies can be a solution to the challenges of this new business model.
